Ignite Creation Date:
2024-05-06 @ 8:11 PM
Last Modification Date:
2024-10-26 @ 3:22 PM
Study NCT ID:
NCT06284317
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-05
First Post:
2024-02-21
Brief Title:
A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy Durvalumab and Surgery in Patients with Early-stage Operable Non-small Cell Lung Cancer
Sponsor:
ETOP IBCSG Partners Foundation
Organization:
ETOP IBCSG Partners Foundation
Organization Data
Organization:
ETOP IBCSG Partners Foundation
Class:
NETWORK
Study ID:
ETOP 25-23
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
ETOP IBCSG Partners Foundation
Lead Sponsor Class:
NETWORK
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| AstraZeneca AG Switzerland | UNKNOWN |